CARLOS
TAXONERA SAMSO
Profesor asociado de Ciencias de la Salud
Pilar
Nos Mateu
Publicaciones en las que colabora con Pilar Nos Mateu (17)
2022
-
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953
2021
-
Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry
Journal of Crohn's and Colitis, Vol. 15, Núm. 1, pp. 35-42
2020
-
Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis
Clinical and translational gastroenterology, Vol. 11, Núm. 8, pp. e00218
-
Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents
Journal of Gastroenterology and Hepatology (Australia), Vol. 35, Núm. 12, pp. 2080-2087
-
Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients
Scientific Reports, Vol. 10, Núm. 1
-
Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry
Alimentary Pharmacology and Therapeutics, Vol. 52, Núm. 6, pp. 1017-1030
-
Switching to a second thiopurine in adult and elderly patients with inflammatory bowel disease: A nationwide study from the eneida registry
Journal of Crohn's and Colitis, Vol. 14, Núm. 9, pp. 1290-1298
2019
-
Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results from the ENEIDA Registry
Inflammatory Bowel Diseases, Vol. 25, Núm. 11, pp. 1862-1870
-
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
Therapeutic Advances in Gastroenterology, Vol. 12
-
Increased risk of thiopurine-related adverse events in elderly patients with IBD
Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 7, pp. 780-788
-
Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial
Digestive and Liver Disease, Vol. 51, Núm. 4, pp. 529-535
-
Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry
Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 3, pp. 278-288
2017
-
Adalimumab vs azathioprine in the prevention of postoperative Crohn's disease recurrence. A GETECCU randomised trial
Journal of Crohn's and Colitis, Vol. 11, Núm. 11, pp. 1293-1301
2016
-
Diagnostic performance of the simple clinical colitis activity index self-administered online at home by patients with ulcerative colitis: CRONICA-UC study
American Journal of Gastroenterology, Vol. 111, Núm. 2, pp. 261-268
-
Erratum: Diagnostic performance of the simple clinical colitis activity index self-administered online at home by patients with ulcerative colitis: CRONICA-UC Study (Am J Gastroenterol (2016) 111 (261268) DOI: 10.1038/ajg.2015.403)
American Journal of Gastroenterology
2013
-
Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era
Alimentary Pharmacology and Therapeutics, Vol. 38, Núm. 7, pp. 752-760
2007
-
Crohn's disease: A review of current treatment with a focus on biologics
Drugs, Vol. 67, Núm. 17, pp. 2511-2537